Ray continued, “We’re also delighted to recognize Martin and Greg’s contributions to Synthekine with their new roles. Martin’s deep insights into cytokine biology and immunology have been instrumental to shaping the event of STK-012, our first-in-class alpha/beta biased IL-2. Its exceptional system expands the therapeutic index of IL-2, among the https://httpswwwzosanopharmacomte51593.bleepblogs.com/37074540/https-www-zosanopharma-com-technology-no-further-a-mystery